INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 S...

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and ...

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update...

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alz...

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on We...

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series...

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences...

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evi...

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK C...

INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference...